Diaceutics and DeepIntent Partner to Transform HCP Engagement with Real Time Diagnostic and Genomic Audiences
Connecting life sciences brands with physicians at the exact moment of treatment decision.
Belfast, UK and New York, NY – November 6, 2025 – Diaceutics, the leading technology and solutions provider leveraging AI-driven diagnostic and genomic data to drive therapy adoption, today announced the availability of its diagnostically driven audiences on DeepIntent’s industry leading healthcare demand side platform (DSP).
The partnership brings a powerful new capability to life sciences marketers: the ability to plan, activate, and optimize campaigns using audiences built on real-world diagnostic, lab, and genomic insights. Unlike traditional claims-based approaches, Diaceutics’ data enables engagement with physicians in real time reflecting what is happening today, not months in the past.
Through the integration, media buyers using DeepIntent can now access over 100 pre-built Diaceutics audience segments spanning general medicine (such as diabetes, CKD, and cardiovascular disease), biomarker-driven oncology therapies (including EGFR+ NSCLC, HER2+ breast cancer, and PD-L1+ prostate cancer), and select rare diseases. These audiences empower marketers to:
- Target HCPs based on a patient’s real clinical journey, from testing to treatment decisions
- Close the recency gap in claims data by activating campaigns on diagnostic and lab triggers
- Uncover hidden treaters not visible in commercial claims datasets but identifiable through diagnostic insights
“In a competitive market, influencing physician behavior depends on timing and context,” said Scott Phillips, VP, Real World Data at Diaceutics. “By partnering with DeepIntent, we’re giving brand and omnichannel teams the ability to act with greater precision reaching physicians in the moment, not after the fact. This is how campaigns become truly impactful.”
DeepIntent empowers healthcare marketers to achieve their brand goals with differentiated data and pharma-specific real-time optimization,” said Natalie Mancuso, SVP, Data Partnerships at DeepIntent. “By bringing Diaceutics’ audiences into our Audience Marketplace, we’re enabling clients to reach HCPs with dynamic signals—connecting at key moments of need to drive stronger engagement, outcomes, and ultimately, better care.
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. For 20 years, Diaceutics has specialized in delivering precision medicine and diagnostic solutions to the world’s top pharma and biotechs. By bridging the gap between biomarker testing and targeted therapies, Diaceutics empowers industry partners to succeed in the evolving field of personalized healthcare.
About DeepIntent
DeepIntent is the leading healthcare demand side platform (DSP), purpose-built to help marketers plan, activate, and optimize data driven campaigns with speed and precision. Trusted by the world’s top healthcare brands and their agencies, DeepIntent uniquely unites media, identity, and real-world clinical data to power privacy safe, omnichannel marketing across every screen. Backed by patented technology and proven outcomes, DeepIntent’s platform delivers measurable audience quality and script lift at scale. Learn more at www.deepintent.com.
